US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc (AUPH) ニュース

AUPH

Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AUPH

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/02	19 : 00	Business Wire	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/05/01	19 : 00	Business Wire	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/30	19 : 00	Business Wire	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/16	23 : 48	Business Wire	UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/15	19 : 00	Business Wire	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/04/09	19 : 00	Business Wire	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06 : 42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/08	06 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/03/01	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/29	22 : 30	Business Wire	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/27	22 : 30	Business Wire	Aurinia to Participate in Upcoming Investor Healthcare Conferences	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 19	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/23	06 : 17	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	20 : 16	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	20 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	20 : 00	Business Wire	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/15	05 : 27	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/02/05	22 : 30	Business Wire	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/01/05	20 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2024/01/05	20 : 00	Business Wire	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2023/12/20	20 : 00	Business Wire	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2023/11/13	20 : 00	Business Wire	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc
2023/11/08	00 : 30	Business Wire	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023	NASDAQ:AUPH	Aurinia Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:AUPH

1 2 3 4 5 6 7 8 9 10 次へ >>

Health Care Select Sector

Energy Select Sector SPDR

Deutsche Telekom (QX)

Invesco QQQ Trust Series 1

US Dollar vs Sterling

JP Morgan Chase

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約